ADULT HEIGHT IN SHORT NORMAL ADOLESCENT GIRLS TREATED WITH GONADOTROPIN-RELEASING-HORMONE ANALOG AND GROWTH-HORMONE

被引:55
作者
BALDUCCI, R
TOSCANO, V
MANGIANTINI, A
MUNICCHI, G
VACCARO, F
PICONE, S
DIRITO, A
BOSCHERINI, B
机构
[1] UNIV ROMA TOR VERGATA, DEPT PEDIAT, I-00133 ROME, ITALY
[2] UNIV ROMA LA SAPIENZA, I-00161 ROME, ITALY
关键词
D O I
10.1210/jc.80.12.3596
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
GnRH analog associated with GH therapy has potential importance for treatment of short stature in subjects without GH deficiency and with a normal onset of puberty. We treated 10 girls with familial short stature with the GnRH analog leuprolide (3.75 mg, im, every 25 days) and GH (0.1 IU/kg . day, sc, 6 days/week). The combined therapies were started simultaneously, and the patients were treated for 28.1 +/- 5.4 (range, 24-36) months. At the onset of treatment, chronological age was 11.6 +/- 1.4 yr, bone age was 10.6 +/- 0.9 yr, height was -2.7 +/- 0.7 SD, predicted height (PH; Bayley-Pinneau score) was 143.2 +/- 3 cm. Target height was 147.6 +/- 5.6 cm. Tanner stage was II-III for breast and genitalia. During treatment, puberty was completely suppressed in all patients. Statistical analysis was performed using Student's t test for paired data. After 12 months of treatment, we observed a significant (P < 0.02) improvement of predicted height (146.2 +/- 3.4 cm). This improvement remained significant (147.6 +/- 3.5; P < 0.001) when treatment was withdrawn. At that time, chronological age was 13.9 +/- 1.2 yr, and bone age was 12.4 +/- 0.7 yr. At the present time (3 +/- 0.97 yr after discontinuation), all of the girls have reached a final height of 144.6 +/- 3 cm (range, 140-149.3 cm). The final height is not significantly different compared with the PH at the beginning of treatment or with target height. These data show that in our patients, combined treatment with GnRH analog-and GH, despite a significant improvement in PH during therapy and upon its withdrawal, does not result in a significant increase in adult stature. Larger and perhaps more prolonged studies in patients of both sexes are required to reach definitive conclusions. Nevertheless, the cost of this treatment in terms of both subject compliance and economic cost should be weighed against the small height gain, if any, that may be achieved.
引用
收藏
页码:3596 / 3600
页数:5
相关论文
共 30 条
[2]  
ALBERTSSONWIKLAND K, 1988, ACTA PAEDIATR SCAND, P77
[3]   FINAL HEIGHT IN GIRLS WITH CENTRAL PRECOCIOUS PUBERTY - COMPARISON OF 2 DIFFERENT LUTEINIZING-HORMONE-RELEASING HORMONE AGONIST TREATMENTS [J].
ANTONIAZZI, F ;
CISTERNINO, M ;
NIZZOLI, G ;
BOZZOLA, M ;
CORRIAS, A ;
DELUCA, F ;
DESANCTIS, C ;
RIGON, F ;
ZAMBONI, G ;
BERNASCONI, S ;
CHIUMELLO, G ;
SEVERI, F ;
TATO, L .
ACTA PAEDIATRICA, 1994, 83 (10) :1052-1056
[4]  
BALDUCCI R, 1992, 74TH P ANN M END SOC, P280
[5]   TABLES FOR PREDICTING ADULT HEIGHT FROM SKELETAL AGE - REVISED FOR USE WITH THE GREULICH-PYLE HAND STANDARDS [J].
BAYLEY, N ;
PINNEAU, SR .
JOURNAL OF PEDIATRICS, 1952, 40 (04) :423-441
[6]  
BOEPPLE PA, 1991, PEDIATR RES, V29, pA74
[7]   ADULT HEIGHT IN GIRLS WITH IDIOPATHIC TRUE PRECOCIOUS PUBERTY [J].
BRAUNER, R ;
ADAN, L ;
MALANDRY, F ;
ZANTLEIFER, D .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (02) :415-420
[8]   LONG-TERM FOLLOW-UP AND FINAL HEIGHT IN GIRLS WITH CENTRAL PRECOCIOUS PUBERTY TREATED WITH LUTEINIZING-HORMONE-RELEASING HORMONE ANALOG NASAL SPRAY [J].
CACCIARI, E ;
CASSIO, A ;
BALSAMO, A ;
COLLI, C ;
CICOGNANI, A ;
PIRAZZOLI, P ;
TANI, G ;
BRONDELLI, L ;
MANDINI, M ;
BOVICELLI, L .
ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 1994, 148 (11) :1194-1199
[9]  
Greulich W, 1969, RADIOGRAPHIC ATLAS S
[10]  
HINDMARSH PC, 1990, ACTA PAEDIATR SCAND, P6